Mankind Pharma Ltd - 543904 - Intimation Regarding Submission Of Application For Reclassification From Promoter & Promoter Group Category To Public Category Under Regulation 31A(8) Of The SEBI (LODR) Regulations, 2015.
Submission of application for reclassification from Promoter & Promoter Group category to Public Category under Regulation 31A of the SEBI (LODR) Regulations, 2015 Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation in Investor Conference - Update
Mankind Pharma share price hits all-time high after FTSE Global inclusion
Share price of Mankind Pharma jumped 4.79% to 2,012 on Monday's trading session after the pharma stock was added to the FTSE All-World, Large-Cap, Total-Cap, and All-Cap indices. Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation in Investors Meeting Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation in Investor Conference Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, please find attached the transcript of the Investor Conference Call for Q2FY24 held on November 01, 2023.
Mankind Pharma Share Price Live blog for 07 Nov 2023
Mankind Pharma stock price went down today, 07 Nov 2023, by -1.07 %. The stock closed at 1775.4 per share. The stock is currently trading at 1756.35 per share. Investors should monitor Mankind Pharma stock price closely in the coming days and weeks to see how it reacts to the news.
Mankind Pharma share price in focus as shareholder lock-in period ends today
Around 70% of the outstanding Mankind Pharma shares will get unlocked and be eligible for trading today.
Mankind share price dips more than 1%- Analysts expect domestic growth to bounce back after some softness seen in Q2
Q2 Results Review- Mankind Pharma tepid domestic revenue growth at 7% was attributed to weakness in the acute segment and soft growth in over the counter selling products. Higher Chronic products sales and rising exports while were positive , analysts expect growth to rebound moving forward Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation in Investor Conference on November 06, 2023